Abstract:Our study indicated that the 14‐gene‐related prognostic signature gene could serve as a novel biomarker for predicting breast cancer patients' prognosis. We found that immunotherapy might play a vital role in therapeutic schedule based on the level and difference of immune‐related cells and pathways in different risk groups. Background Breast cancer (BC), a malignant tumor, is a significant cause of death and disability among women globally. Recent research indicates that copy number variation plays a crucial role in tumor development. In this study, we employed the Single‐Cell Variational Aneuploidy Analysis (SCEVAN) algorithm to differentiate between malignant and non‐malignant cells, aiming to identify genetic signatures with prognostic relevance for predicting patient survival. Methods We analyzed gene expression profiles and associated clinical data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Using the SCEVAN algorithm, we distinguished malignant from non‐malignant cells and investigated cellular interactions within the tumor microenvironment (TME). We categorized TCGA samples based on differentially expressed genes (DEGs) between these cell types. Subsequent Kyoto Encyclopedia of Genes and Genomes pathway analysis was conducted. Additionally, we developed polygenic models for the DEGs using least absolute shrinkage and selection operator‐penalized Cox regression analysis. To assess the prognostic accuracy of these characteristics, we generated Kaplan–Meier and receiver operating characteristic curves from training and validation datasets. We also monitored the expression variations of prognostic genes across the pseudotime of malignant cells. Patients were divided into high‐risk and low‐risk groups based on median risk scores to compare their TME and identify potential therapeutic agents. Lastly, polymerase chain reaction was used to validate seven pivotal genes. Results The SCEVAN algorithm identified distinct malignant and non‐malignant cells in GSE180286. Cellchat analysis revealed significantly increased cellular communication, particularly between fibroblasts, endothelial cells and malignant cells. The DEGs were predominantly involved in immune‐related pathways. TCGA samples were classified into clusters A and B based on these genes. Cluster A, enriched in immune pathways, was associated with poorer prognosis, whereas cluster B, predominantly involved in circadian rhythm pathways, showed better outcomes. We constructed a 14‐gene prognostic signature, validated in a 1:1 internal TCGA cohort and external GEO datasets (GSE42568 and GSE146558). Kaplan–Meier analysis confirmed the prognostic signature's accuracy (p

Novel 2 Gene Signatures Associated With Breast Cancer Proliferation: Insights From Predictive Differential Gene Expression Analysis

Biomarker Discovery To Improve Prediction Of Breast Cancer Survival: Using Gene Expression Profiling, Meta-Analysis, And Tissue Validation

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis

Identification of novel cell glycolysis related gene signature predicting survival in patients with breast cancer

Identification of a six-gene signature associated with tumor mutation burden for predicting prognosis in patients with invasive breast carcinoma

Identification of Breast Cancer Candidate Genes Using Gene Co-Expression and Protein-Protein Interaction Information

Comprehensive analysis of gene expression profiles to identify differential prognostic factors of primary and metastatic breast cancer

G2M checkpoint signaling among six-cell proliferation-related pathway as a biomarker for prediction and prognosis in pancreatic cancer.

Development of a novel prognostic signature based on single‐cell combined bulk RNA analysis in breast cancer

A genome-wide systematic analysis reveals different and predictive proliferation expression signatures of cancerous vs. non-cancerous cells

Up-regulation of FN1, Activation of Maturation Promoting Factor and Associated Signaling Pathway Facilitates Epithelial-Mesenchymal Transition, Inhibits Apoptosis and Elevates Proliferation Rate of Breast Cancer Cells: In Silico Analysis of Microarray Datasets

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (-) Breast Cancer

Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer

Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis

Correction To: Identification of a Five Genes Prognosis Signature for Triple-Negative Breast Cancer Using Multi-Omics Methods and Bioinformatics Analysis

A Novel Gene Prognostic Signature Based on Differential DNA Methylation in Breast Cancer.

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

A Novel Glycolysis-Related Four-mRNA Signature for Predicting the Survival of Patients With Breast Cancer

Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data

A Novel Signature Based on Cancer-Associated Fibroblast Genes to Predict Prognosis, Immune Feature, and Therapeutic Response in Breast Cancer.